The public benefit company, born of a partnership of Boston-area universities, hospitals, and private industry led by Harvard and MIT, named former Orchard Therapeutics, Amgen, and Genzyme executive Ran Zheng its chief executive. Zheng, who started earlier this year, said that the project has been renamed Landmark Bio. It had been called the Center for Advanced Biological Innovation and Manufacturing since it was formed in 2019.
July 29, 2021
More posts by Park Square Executive Search
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at email@example.com